The de novo variants in the other proteins of this group (CaMKIIα and CaMKIIβ) have been clearly described in patients with neurodevelopmental disorders [10,11], while there is still some lack of evidence for the CaMKIIγ variants that were found both in patients and the control (OMIM: 618522). This evidence concerns the gene CAMK2B and neurodevelopmental disorder.